Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
Authors
Keywords
Vascular Endothelial Growth Factor, Renal Cell Carcinoma, Bevacizumab, Sorafenib, Sunitinib
Journal
DRUGS
Volume 73, Issue 5, Pages 427-438
Publisher
Springer Nature
Online
2013-04-09
DOI
10.1007/s40265-013-0043-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) B. Escudier et al. ANNALS OF ONCOLOGY
- Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
- (2012) S Bracarda et al. BRITISH JOURNAL OF CANCER
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
- (2012) Allan Lipton et al. EUROPEAN JOURNAL OF CANCER
- Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
- (2012) W. M. Linehan GENOME RESEARCH
- Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- (2012) Laurence Albiges et al. JOURNAL OF CLINICAL ONCOLOGY
- Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials
- (2012) Sujata Patil et al. JOURNAL OF UROLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-Clear Cell Renal Cell Carcinoma: Does the Mammalian Target of Rapamycin Represent a Rational Therapeutic Target?
- (2012) L. Albiges et al. ONCOLOGIST
- Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma
- (2011) Sarmad Sadeghi et al. CANCER
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
- (2011) Ana M. Molina et al. CANCER
- Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- (2011) Judith Manola et al. CLINICAL CANCER RESEARCH
- Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
- (2011) Irfan Kayani et al. CLINICAL CANCER RESEARCH
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
- (2011) E. Calvo et al. EUROPEAN JOURNAL OF CANCER
- Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- (2011) Katherine M. Krajewski et al. EUROPEAN UROLOGY
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- (2011) Ignacio Varela et al. NATURE
- A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
- (2011) Corine Bertolotto et al. NATURE
- Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy
- (2010) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
- (2010) S. Patil et al. ANNALS OF ONCOLOGY
- Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial
- (2010) Sergio Bracarda et al. BJU INTERNATIONAL
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- (2010) Ivan N. Zama et al. CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
- (2010) N. Lassau et al. CLINICAL CANCER RESEARCH
- Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
- (2010) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
- (2010) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- (2010) Jose A. Karam et al. JOURNAL OF UROLOGY
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
- (2010) Gillian L. Dalgliesh et al. NATURE
- Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy
- (2010) Michael M. Vickers et al. UROLOGY
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. Clinical Genitourinary Cancer
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- (2009) Premal H. Patel et al. Clinical Genitourinary Cancer
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- (2009) Daniel C. Cho et al. JOURNAL OF IMMUNOTHERAPY
- Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
- (2009) M.P. Sablin et al. JOURNAL OF UROLOGY
- Renal cell carcinoma
- (2009) Brian I Rini et al. LANCET
- Birt-Hogg-Dubé syndrome: diagnosis and management
- (2009) Fred H Menko et al. LANCET ONCOLOGY
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
- (2008) Arkadiusz Z. Dudek et al. CANCER
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
- (2008) John D. Gordan et al. CANCER CELL
- Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
- (2008) Manfred Johannsen et al. EUROPEAN UROLOGY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy
- (2008) Ali Reza Golshayan et al. JOURNAL OF CLINICAL ONCOLOGY
- von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
- (2008) Toni K. Choueiri et al. JOURNAL OF UROLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
- (2007) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started